Terumo Corp
TSE:4543

Watchlist Manager
Terumo Corp Logo
Terumo Corp
TSE:4543
Watchlist
Price: 3 030 JPY -0.16% Market Closed
Market Cap: 4.5T JPY
Have any thoughts about
Terumo Corp?
Write Note

Terumo Corp
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Terumo Corp
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Terumo Corp
TSE:4543
Total Liabilities & Equity
ÂĄ1.8T
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
7%
Olympus Corp
TSE:7733
Total Liabilities & Equity
ÂĄ1.4T
CAGR 3-Years
5%
CAGR 5-Years
7%
CAGR 10-Years
3%
Sysmex Corp
TSE:6869
Total Liabilities & Equity
ÂĄ618.1B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
11%
Nihon Kohden Corp
TSE:6849
Total Liabilities & Equity
ÂĄ218.6B
CAGR 3-Years
5%
CAGR 5-Years
7%
CAGR 10-Years
6%
JEOL Ltd
TSE:6951
Total Liabilities & Equity
ÂĄ229.7B
CAGR 3-Years
11%
CAGR 5-Years
13%
CAGR 10-Years
8%
Fukuda Denshi Co Ltd
TSE:6960
Total Liabilities & Equity
ÂĄ204.8B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
6%
No Stocks Found

Terumo Corp
Glance View

Market Cap
4.5T JPY
Industry
Health Care

In the bustling corridors of Tokyo, Terumo Corporation stands as a testament to Japan's prowess in medical innovation, deeply rooted in a legacy that began over 90 years ago. Born from the vision of a group of scientists aiming to improve Japan’s healthcare system, Terumo embarked on its journey by developing high-quality thermometers. This modest start set the stage for what would become a global leader in medical technology. Anchored by its commitment to enhancing patient care and healthcare practices, Terumo carved out a significant niche by focusing on cardiovascular systems, blood transfusion, and cell therapy technologies. As the company grew, it systematically increased its range, moving into areas such as vascular intervention and diabetes care, aligning with evolving medical needs around the globe. Today, Terumo generates its revenue through a multi-faceted business model that thrives on innovation and globalization. It operates through several segments: Cardiovascular, General Hospital, and Blood Management. The Cardiovascular division, a major revenue driver, offers products ranging from stents to heart-lung machines used in cardiac surgeries. Meanwhile, the General Hospital unit provides hospital equipment like infusion pumps and syringe systems, while the Blood Management segment is renowned for its blood and cell processing systems. Terumo’s ability to innovate within these domains enhances its competitive edge by delivering cutting-edge medical solutions. By balancing its expansive product portfolio with a strong focus on research and development, the company not only sustains but frequently advances the standards of modern healthcare, ensuring its continued success in diverse international markets.

Intrinsic Value
2 434.6 JPY
Overvaluation 20%
Intrinsic Value
Price

See Also

What is Terumo Corp's Total Liabilities & Equity?
Total Liabilities & Equity
1.8T JPY

Based on the financial report for Sep 30, 2024, Terumo Corp's Total Liabilities & Equity amounts to 1.8T JPY.

What is Terumo Corp's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
7%

Over the last year, the Total Liabilities & Equity growth was 0%. The average annual Total Liabilities & Equity growth rates for Terumo Corp have been 9% over the past three years , 9% over the past five years , and 7% over the past ten years .

Back to Top